MONMOUTHJUNCTION, NJ,November14, 2019 – Matt Kuruc from Biotech Support Group gave apresentation entitled “StromaLiquid Biopsy™ - Blood-based biomarkers to monitor stromalconditioning in cancer” at the Companion Diagnostics Forum, October30, 2019 in Princeton NJ.
 

Thetalk described how commercial enthusiasm continues for the prospectsof characterizing cancerous tissue non-invasively through liquidbiopsy biomarkers. However, the vast majority of the biomarkers beinginvestigated serve to report the landscape of DNA mutationsassociated with tumor burden; only part of the full picture ofprogressive disease. The other largely neglected part of tumorprogression, comes from the cooperation of the normal host responseto local inflammation. This stromalconditioning assists thetumor ecosystem so that ultimately signalsoriginating in the primary tumor enable cancer cells to enter thegeneral blood circulationand metastasize to distant sites. Such metastatic potentiation is notreportable from gene-centric liquid biopsy data.

TheStroma Liquid Biopsy™ pan-cancer biomarker panel opens the door tomonitor this cooperation using blood rather than tissue. The proteinpanel categorically connects with a host’s innate immune response –the first responder team to local inflammation: coagulation(platelets), complement (crosstalk to adaptive immunity) andneutrophil recruitment. All these pathways are interconnected,activated by proteolysis, and regulated by protease inhibition.Because proteolysis is irreversible, all species of life have evolvedmolecular regulatory systems to control aberrancies. The mostdistinguished is a protease inhibitory family of regulators known asSerpins.

Thetalk describes how micro-environmental changes in tumors aresufficient to distort the ratio of cleaved inactive serpinforms from intact active serpin forms, and that these ratiosare sufficiently differentiated so as to be reportable in the generalblood circulation. Serpins A1 (Alpha-1-Antitrypsin) and D1 (HeparinCofactor II) primarily regulate the activities of the inflammatoryproteases elastase and thrombin respectively. Using functional enzymeassays, preliminary results correlate to LC-MS/MS results, confirminga significant increase in the cleaved/total ratio in cancer sera,corresponding to a net decrease in inhibitory active serpin, relativeto a normal/healthy status.

SwapanRoy, Ph.D., President and Founder of Biotech Support Group, concursstating “Although Serpinscirculate in a variety of functional on/off sub-forms, they have beenpreviously observed and reported byimmunologicalmethods (ELISA). This can lead to egregiously misleadinginterpretation of a host’s systemic response to cancer, as theimmunological assay measures in aggregate the functionally oppositeintact and cleaved serpin forms.Significantly, cancerpatients have a greater amount of cleaved Serpin forms relative tonormal.Our intellectualproperty now opens up the ability to monitor this important stromalinfluence in the progression of cancer, presenting many precisionmedicine possibilities. 

DownloadCompanion Diagnostics Forum presentation at:

https://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/Companion%20Diagnostics%20Forum.pdf

Formore information on the BSG complete line of Albumin& IgG Removal products,visit: https://www.biotechsupportgroup.com/Articles.asp?ID=451

Todiscuss license, collaboration and partnership opportunities, pleasecontact

Contact:
MatthewKuruc 732-274-2866

[email protected]

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, go tohttp://www.biotechsupportgroup.com